Key clinical point: Degarelix and leuprolide showed no difference in major adverse cardiovascular events (MACEs) at 1 year in patients with prostate cancer.

Major finding: There was no significant difference in the incidence of MACEs between degarelix and leuprolide groups (5.5% vs 4.1%; hazard ratio [HR], 1.28; P = .53). The rate of disease progression was similar between the groups (HR, 0.89; 95% confidence interval, 0.51-1.54). A lower rate of injection site reactions was seen with degarelix vs leuprolide (60.4% vs 26.8%).

Study details: A randomized, open-label, multinational phase 3 PRONOUNCE trial of 545 patients with prostate cancer and established atherosclerotic cardiovascular disease who were randomly assigned to receive degarelix or leuprolide.

Disclosures: This work was supported by Ferring Pharmaceuticals. The authors received grants, consulting/personal fees, membership fees, honoraria, and/or nonfinancial support from various sources. Some of the authors reported being employed at pharmaceutical companies.

Source: Lopes RD et al. Circulation. 2021 Aug 30. doi: 10.1161/CIRCULATIONAHA.121.056810.

Key clinical point: Degarelix and leuprolide showed no difference in major adverse cardiovascular events (MACEs) at 1 year in patients with prostate cancer.

Major finding: There was no significant difference in the incidence of MACEs between degarelix and leuprolide groups (5.5% vs 4.1%; hazard ratio [HR], 1.28; P = .53). The rate of disease progression was similar between the groups (HR, 0.89; 95% confidence interval, 0.51-1.54). A lower rate of injection site reactions was seen with degarelix vs leuprolide (60.4% vs 26.8%).

Study details: A randomized, open-label, multinational phase 3 PRONOUNCE trial of 545 patients with prostate cancer and established atherosclerotic cardiovascular disease who were randomly assigned to receive degarelix or leuprolide.

Disclosures: This work was supported by Ferring Pharmaceuticals. The authors received grants, consulting/personal fees, membership fees, honoraria, and/or nonfinancial support from various sources. Some of the authors reported being employed at pharmaceutical companies.

Source: Lopes RD et al. Circulation. 2021 Aug 30. doi: 10.1161/CIRCULATIONAHA.121.056810.

Key clinical point: Degarelix and leuprolide showed no difference in major adverse cardiovascular events (MACEs) at 1 year in patients with prostate cancer.

Major finding: There was no significant difference in the incidence of MACEs between degarelix and leuprolide groups (5.5% vs 4.1%; hazard ratio [HR], 1.28; P = .53). The rate of disease progression was similar between the groups (HR, 0.89; 95% confidence interval, 0.51-1.54). A lower rate of injection site reactions was seen with degarelix vs leuprolide (60.4% vs 26.8%).

Study details: A randomized, open-label, multinational phase 3 PRONOUNCE trial of 545 patients with prostate cancer and established atherosclerotic cardiovascular disease who were randomly assigned to receive degarelix or leuprolide.

Disclosures: This work was supported by Ferring Pharmaceuticals. The authors received grants, consulting/personal fees, membership fees, honoraria, and/or nonfinancial support from various sources. Some of the authors reported being employed at pharmaceutical companies.

Source: Lopes RD et al. Circulation. 2021 Aug 30. doi: 10.1161/CIRCULATIONAHA.121.056810.

Key clinical point: In a long-term follow-up, adding short-term androgen deprivation therapy (ADT) to radiotherapy in patients with localized prostate cancer does not show overall survival (OS) benefit after 15 years.

Major finding: The OS curves of the 2 groups converge at 15 years. In the radiotherapy-alone vs combination treatment group, the OS rate at 18 years was 23% vs 23% (hazard ratio, 0.94; P =.94).

Study details: A randomized, phase 3 NRG/RTOG 9408 study of 2,028 patients with localized prostate cancer and prostate-specific antigen of ≤20 ng/mL who were randomly assigned to radiotherapy alone or radiotherapy plus short-term ADT.

Disclosures: This work was supported by National Cancer Institute. The authors performed advisory/consulting roles, received personal fees/grants and/or salary/stipend, chaired committees, and/or were employed by/owned stocks in pharmaceutical companies.

Source: Jones CU et al. Int J Radiat Oncol Biol Phys. 2021 Aug 31. doi: 10.1016/j.ijrobp.2021.08.031.

Key clinical point: In a long-term follow-up, adding short-term androgen deprivation therapy (ADT) to radiotherapy in patients with localized prostate cancer does not show overall survival (OS) benefit after 15 years.

Major finding: The OS curves of the 2 groups converge at 15 years. In the radiotherapy-alone vs combination treatment group, the OS rate at 18 years was 23% vs 23% (hazard ratio, 0.94; P =.94).

Study details: A randomized, phase 3 NRG/RTOG 9408 study of 2,028 patients with localized prostate cancer and prostate-specific antigen of ≤20 ng/mL who were randomly assigned to radiotherapy alone or radiotherapy plus short-term ADT.

Disclosures: This work was supported by National Cancer Institute. The authors performed advisory/consulting roles, received personal fees/grants and/or salary/stipend, chaired committees, and/or were employed by/owned stocks in pharmaceutical companies.

Source: Jones CU et al. Int J Radiat Oncol Biol Phys. 2021 Aug 31. doi: 10.1016/j.ijrobp.2021.08.031.

Key clinical point: In a long-term follow-up, adding short-term androgen deprivation therapy (ADT) to radiotherapy in patients with localized prostate cancer does not show overall survival (OS) benefit after 15 years.

Major finding: The OS curves of the 2 groups converge at 15 years. In the radiotherapy-alone vs combination treatment group, the OS rate at 18 years was 23% vs 23% (hazard ratio, 0.94; P =.94).

Study details: A randomized, phase 3 NRG/RTOG 9408 study of 2,028 patients with localized prostate cancer and prostate-specific antigen of ≤20 ng/mL who were randomly assigned to radiotherapy alone or radiotherapy plus short-term ADT.

Disclosures: This work was supported by National Cancer Institute. The authors performed advisory/consulting roles, received personal fees/grants and/or salary/stipend, chaired committees, and/or were employed by/owned stocks in pharmaceutical companies.

Source: Jones CU et al. Int J Radiat Oncol Biol Phys. 2021 Aug 31. doi: 10.1016/j.ijrobp.2021.08.031.

Key clinical point: Patient-reported outcomes were similar with hypofractionated vs. conventional radiotherapy at 5 years in patients with prostate cancer.

Major finding: There were no differences in the Expanded Prostate Cancer Index Composite or University of California Los Angeles Prostate Cancer Index in the overall bowel, urinary, and sexual symptoms between the 3 groups at 5 years.

Study details: Quality of life substudy of phase 3 randomized CHHiP trial of 2,100 patients with intermediate-risk prostate cancer who received conventional (74 Gy in 37 fractions over 7.4 weeks) or hypofractionated (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) radiotherapy.

Disclosures: This study was supported by Cancer Research UK, Institute for Health Research Cancer Research Network, and National Health Service.

Source: Staffurth JN et al. Eur Urol Oncol. 2021 Sep 3. doi: 10.1016/j.euo.2021.07.005.

Key clinical point: Patient-reported outcomes were similar with hypofractionated vs. conventional radiotherapy at 5 years in patients with prostate cancer.

Major finding: There were no differences in the Expanded Prostate Cancer Index Composite or University of California Los Angeles Prostate Cancer Index in the overall bowel, urinary, and sexual symptoms between the 3 groups at 5 years.

Study details: Quality of life substudy of phase 3 randomized CHHiP trial of 2,100 patients with intermediate-risk prostate cancer who received conventional (74 Gy in 37 fractions over 7.4 weeks) or hypofractionated (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) radiotherapy.

Disclosures: This study was supported by Cancer Research UK, Institute for Health Research Cancer Research Network, and National Health Service.

Source: Staffurth JN et al. Eur Urol Oncol. 2021 Sep 3. doi: 10.1016/j.euo.2021.07.005.

Key clinical point: Patient-reported outcomes were similar with hypofractionated vs. conventional radiotherapy at 5 years in patients with prostate cancer.

Major finding: There were no differences in the Expanded Prostate Cancer Index Composite or University of California Los Angeles Prostate Cancer Index in the overall bowel, urinary, and sexual symptoms between the 3 groups at 5 years.

Study details: Quality of life substudy of phase 3 randomized CHHiP trial of 2,100 patients with intermediate-risk prostate cancer who received conventional (74 Gy in 37 fractions over 7.4 weeks) or hypofractionated (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) radiotherapy.

Disclosures: This study was supported by Cancer Research UK, Institute for Health Research Cancer Research Network, and National Health Service.

Source: Staffurth JN et al. Eur Urol Oncol. 2021 Sep 3. doi: 10.1016/j.euo.2021.07.005.

Key clinical point: Overall health-related quality of life (HRQoL) was maintained with the addition of apalutamide to androgen deprivation therapy (ADT) in patients with nonmetastatic castration-resistant prostate cancer (CRPC).

Major finding: The change in Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score significantly favored apalutamide vs placebo at treatment cycles 21 (P = .0138) and 25 (P = .0009). No difference was seen in the median time to deterioration in scores for FACT-P and subscales.

Study details: HRQoL analysis of phase 3, randomized SPARTAN trial of patients with nmCRPC who were randomly assigned to receive apalutamide or placebo. All patients continued ADT.

Disclosures: This study was funded by Janssen Research & Development. The authors received consulting/personal/advisory/speaker fees, honoraria, royalties, research funding, lectureship fees, and/or travel expenses from various sources. Some authors reported being an investigator in clinical trials and stock ownership in pharmaceutical companies.

Source: Oudard S et al. Eur Urol Focus. 2021 Aug 31. doi: 10.1016/j.euf.2021.08.005.

Key clinical point: Overall health-related quality of life (HRQoL) was maintained with the addition of apalutamide to androgen deprivation therapy (ADT) in patients with nonmetastatic castration-resistant prostate cancer (CRPC).

Major finding: The change in Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score significantly favored apalutamide vs placebo at treatment cycles 21 (P = .0138) and 25 (P = .0009). No difference was seen in the median time to deterioration in scores for FACT-P and subscales.

Study details: HRQoL analysis of phase 3, randomized SPARTAN trial of patients with nmCRPC who were randomly assigned to receive apalutamide or placebo. All patients continued ADT.

Disclosures: This study was funded by Janssen Research & Development. The authors received consulting/personal/advisory/speaker fees, honoraria, royalties, research funding, lectureship fees, and/or travel expenses from various sources. Some authors reported being an investigator in clinical trials and stock ownership in pharmaceutical companies.

Source: Oudard S et al. Eur Urol Focus. 2021 Aug 31. doi: 10.1016/j.euf.2021.08.005.

Key clinical point: Overall health-related quality of life (HRQoL) was maintained with the addition of apalutamide to androgen deprivation therapy (ADT) in patients with nonmetastatic castration-resistant prostate cancer (CRPC).

Major finding: The change in Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score significantly favored apalutamide vs placebo at treatment cycles 21 (P = .0138) and 25 (P = .0009). No difference was seen in the median time to deterioration in scores for FACT-P and subscales.

Study details: HRQoL analysis of phase 3, randomized SPARTAN trial of patients with nmCRPC who were randomly assigned to receive apalutamide or placebo. All patients continued ADT.

Disclosures: This study was funded by Janssen Research & Development. The authors received consulting/personal/advisory/speaker fees, honoraria, royalties, research funding, lectureship fees, and/or travel expenses from various sources. Some authors reported being an investigator in clinical trials and stock ownership in pharmaceutical companies.

Source: Oudard S et al. Eur Urol Focus. 2021 Aug 31. doi: 10.1016/j.euf.2021.08.005.

Key clinical point: The incidence of ramucirumab-induced infusion-related reaction (IRR) was low in patients with advanced colorectal cancer (CRC) who did not receive antihistamine premedication. Moreover, not using antihistamine premedication can reduce medical costs.

Major finding: Overall, IRR was reported in 2 patients (1.4%), both of whom received antihistamine and steroids before the ramucirumab infusion. IRRs were not observed in 41 patients without antihistamine premedication, and these patients were significantly less likely to have IRR vs the previous report of cetuximab (P < .001).

Study details: This was a retrospective, observational study including 147 patients with unresectable CRC who received ramucirumab+FOLFIRI therapy.

Disclosures: The study did not receive any funding. The authors declared no conflict of interests.

Source: Okuyama H et al. Int J Clin Oncol. 2021 Sep 2. doi: 10.1007/s10147-021-02004-9.

Key clinical point: The incidence of ramucirumab-induced infusion-related reaction (IRR) was low in patients with advanced colorectal cancer (CRC) who did not receive antihistamine premedication. Moreover, not using antihistamine premedication can reduce medical costs.

Major finding: Overall, IRR was reported in 2 patients (1.4%), both of whom received antihistamine and steroids before the ramucirumab infusion. IRRs were not observed in 41 patients without antihistamine premedication, and these patients were significantly less likely to have IRR vs the previous report of cetuximab (P < .001).

Study details: This was a retrospective, observational study including 147 patients with unresectable CRC who received ramucirumab+FOLFIRI therapy.

Disclosures: The study did not receive any funding. The authors declared no conflict of interests.

Source: Okuyama H et al. Int J Clin Oncol. 2021 Sep 2. doi: 10.1007/s10147-021-02004-9.

Key clinical point: The incidence of ramucirumab-induced infusion-related reaction (IRR) was low in patients with advanced colorectal cancer (CRC) who did not receive antihistamine premedication. Moreover, not using antihistamine premedication can reduce medical costs.

Major finding: Overall, IRR was reported in 2 patients (1.4%), both of whom received antihistamine and steroids before the ramucirumab infusion. IRRs were not observed in 41 patients without antihistamine premedication, and these patients were significantly less likely to have IRR vs the previous report of cetuximab (P < .001).

Study details: This was a retrospective, observational study including 147 patients with unresectable CRC who received ramucirumab+FOLFIRI therapy.

Disclosures: The study did not receive any funding. The authors declared no conflict of interests.

Source: Okuyama H et al. Int J Clin Oncol. 2021 Sep 2. doi: 10.1007/s10147-021-02004-9.

Key clinical point: Long-term oncological outcomes after colorectal surgery were not significantly different among patients with ulcerative colitis-associated colorectal cancer (CRC) and sporadic CRC.

Major finding: Disease-free survival (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.85-1.32), recurrence-free survival (HR, 1.14; 95% CI, 0.86-1.53), and all-cause mortality (HR, 1.15; 95% CI, 0.89-1.48) were similar between the group of patients with ulcerative colitis-associated and sporadic CRC.

Study details: This observational cohort study included 1,332 patients who underwent surgery with curative intent for CRC including 222 patients with a preoperative diagnosis of ulcerative colitis who were matched with 1,110 patients with sporadic CRC.

Disclosures: The study did not receive any funding. The authors declared no commercial interest in the subject of the study.

Source: Lin VA et al. Ann Surg Oncol. 2021 Sep 5. doi: 10.1245/s10434-021-10759-8.

Key clinical point: Long-term oncological outcomes after colorectal surgery were not significantly different among patients with ulcerative colitis-associated colorectal cancer (CRC) and sporadic CRC.

Major finding: Disease-free survival (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.85-1.32), recurrence-free survival (HR, 1.14; 95% CI, 0.86-1.53), and all-cause mortality (HR, 1.15; 95% CI, 0.89-1.48) were similar between the group of patients with ulcerative colitis-associated and sporadic CRC.

Study details: This observational cohort study included 1,332 patients who underwent surgery with curative intent for CRC including 222 patients with a preoperative diagnosis of ulcerative colitis who were matched with 1,110 patients with sporadic CRC.

Disclosures: The study did not receive any funding. The authors declared no commercial interest in the subject of the study.

Source: Lin VA et al. Ann Surg Oncol. 2021 Sep 5. doi: 10.1245/s10434-021-10759-8.

Key clinical point: Long-term oncological outcomes after colorectal surgery were not significantly different among patients with ulcerative colitis-associated colorectal cancer (CRC) and sporadic CRC.

Major finding: Disease-free survival (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.85-1.32), recurrence-free survival (HR, 1.14; 95% CI, 0.86-1.53), and all-cause mortality (HR, 1.15; 95% CI, 0.89-1.48) were similar between the group of patients with ulcerative colitis-associated and sporadic CRC.

Study details: This observational cohort study included 1,332 patients who underwent surgery with curative intent for CRC including 222 patients with a preoperative diagnosis of ulcerative colitis who were matched with 1,110 patients with sporadic CRC.

Disclosures: The study did not receive any funding. The authors declared no commercial interest in the subject of the study.

Source: Lin VA et al. Ann Surg Oncol. 2021 Sep 5. doi: 10.1245/s10434-021-10759-8.

Key clinical point: The combination of S-1 and oxaliplatin (SOX) with bevacizumab (B-mab) or cetuximab (C-mab) had almost similar efficacy and safety as first-line chemotherapy for previously untreated recurrent advanced colorectal cancer (CRC) with wild-type KRAS.

Major finding: The overall response rates in the SOX+B-mab and SOX+C-mab arms were 59.1% and 43.5% (P = .29) and disease control rates were 90.9% and 91.3% (P = .96), respectively. The median overall survival (25.3 months vs 15.5 months; P = .167) and median progression-free survival (11.7 months vs 5.5 months; P = .077) were similar for SOX+B-mab and SOX+C-mab groups. Grade 3 or more adverse events were reported by 45.6% and 47.8% of patients in the SOX+B-mab and SOX+C-mab groups, respectively.

Study details: This was a randomized, phase 2 trial including 45 patients with previously untreated, locally advanced, or metastatic CRC with wild-type KRAS randomly assigned to SOX+B-mab or SOX+C-mab.

Disclosures: The study did not receive any specific grant from funding agencies. The authors declared no conflict of interests.

Source: Nishizawa Y et al. BMC Cancer. 2021 Aug 23. doi: 10.1186/s12885-021-08690-y.

Key clinical point: The combination of S-1 and oxaliplatin (SOX) with bevacizumab (B-mab) or cetuximab (C-mab) had almost similar efficacy and safety as first-line chemotherapy for previously untreated recurrent advanced colorectal cancer (CRC) with wild-type KRAS.

Major finding: The overall response rates in the SOX+B-mab and SOX+C-mab arms were 59.1% and 43.5% (P = .29) and disease control rates were 90.9% and 91.3% (P = .96), respectively. The median overall survival (25.3 months vs 15.5 months; P = .167) and median progression-free survival (11.7 months vs 5.5 months; P = .077) were similar for SOX+B-mab and SOX+C-mab groups. Grade 3 or more adverse events were reported by 45.6% and 47.8% of patients in the SOX+B-mab and SOX+C-mab groups, respectively.

Study details: This was a randomized, phase 2 trial including 45 patients with previously untreated, locally advanced, or metastatic CRC with wild-type KRAS randomly assigned to SOX+B-mab or SOX+C-mab.

Disclosures: The study did not receive any specific grant from funding agencies. The authors declared no conflict of interests.

Source: Nishizawa Y et al. BMC Cancer. 2021 Aug 23. doi: 10.1186/s12885-021-08690-y.

Key clinical point: The combination of S-1 and oxaliplatin (SOX) with bevacizumab (B-mab) or cetuximab (C-mab) had almost similar efficacy and safety as first-line chemotherapy for previously untreated recurrent advanced colorectal cancer (CRC) with wild-type KRAS.

Major finding: The overall response rates in the SOX+B-mab and SOX+C-mab arms were 59.1% and 43.5% (P = .29) and disease control rates were 90.9% and 91.3% (P = .96), respectively. The median overall survival (25.3 months vs 15.5 months; P = .167) and median progression-free survival (11.7 months vs 5.5 months; P = .077) were similar for SOX+B-mab and SOX+C-mab groups. Grade 3 or more adverse events were reported by 45.6% and 47.8% of patients in the SOX+B-mab and SOX+C-mab groups, respectively.

Study details: This was a randomized, phase 2 trial including 45 patients with previously untreated, locally advanced, or metastatic CRC with wild-type KRAS randomly assigned to SOX+B-mab or SOX+C-mab.

Disclosures: The study did not receive any specific grant from funding agencies. The authors declared no conflict of interests.

Source: Nishizawa Y et al. BMC Cancer. 2021 Aug 23. doi: 10.1186/s12885-021-08690-y.

Key clinical point: Patients diagnosed with metastatic colorectal cancer (mCRC) after vs. before the COVID-19 lockdown had higher levels of circulating tumor DNA (ctDNA) and shorter survival, indicating the need for interventions to minimize the pandemic-associated diagnostic delay.

Major finding: Patients diagnosed after the lockdown vs. those diagnosed before had a significantly higher ctDNA concentration (119.2 vs 17.3 ng/mL; P < .001). Additionally, the median survival was significantly shorter in patients with ctDNA 24.4 ng/mL or more vs 24.4 ng/mL or lower (14.7 months vs 20.0 months; P = .005).

Study details: This cohort study included 80 patients with newly diagnosed unresectable mCRC from the ongoing phase 2 PANIRINOX trial who underwent screening procedure before (n=40) or after (n=40) the first COVID-19 lockdown in France in 2020.

Disclosures: The PANIRINOX study was funded by Amgen and sponsored by Unicancer Research and Development. Some of the authors declared receiving personal fees and/or grants from various sources including Amgen.

Source: Thierry AR et al. JAMA Netw Open. 2021 Sep 8. doi: 10.1001/jamanetworkopen.2021.24483.

Key clinical point: Patients diagnosed with metastatic colorectal cancer (mCRC) after vs. before the COVID-19 lockdown had higher levels of circulating tumor DNA (ctDNA) and shorter survival, indicating the need for interventions to minimize the pandemic-associated diagnostic delay.

Major finding: Patients diagnosed after the lockdown vs. those diagnosed before had a significantly higher ctDNA concentration (119.2 vs 17.3 ng/mL; P < .001). Additionally, the median survival was significantly shorter in patients with ctDNA 24.4 ng/mL or more vs 24.4 ng/mL or lower (14.7 months vs 20.0 months; P = .005).

Study details: This cohort study included 80 patients with newly diagnosed unresectable mCRC from the ongoing phase 2 PANIRINOX trial who underwent screening procedure before (n=40) or after (n=40) the first COVID-19 lockdown in France in 2020.

Disclosures: The PANIRINOX study was funded by Amgen and sponsored by Unicancer Research and Development. Some of the authors declared receiving personal fees and/or grants from various sources including Amgen.

Source: Thierry AR et al. JAMA Netw Open. 2021 Sep 8. doi: 10.1001/jamanetworkopen.2021.24483.

Key clinical point: Patients diagnosed with metastatic colorectal cancer (mCRC) after vs. before the COVID-19 lockdown had higher levels of circulating tumor DNA (ctDNA) and shorter survival, indicating the need for interventions to minimize the pandemic-associated diagnostic delay.

Major finding: Patients diagnosed after the lockdown vs. those diagnosed before had a significantly higher ctDNA concentration (119.2 vs 17.3 ng/mL; P < .001). Additionally, the median survival was significantly shorter in patients with ctDNA 24.4 ng/mL or more vs 24.4 ng/mL or lower (14.7 months vs 20.0 months; P = .005).

Study details: This cohort study included 80 patients with newly diagnosed unresectable mCRC from the ongoing phase 2 PANIRINOX trial who underwent screening procedure before (n=40) or after (n=40) the first COVID-19 lockdown in France in 2020.

Disclosures: The PANIRINOX study was funded by Amgen and sponsored by Unicancer Research and Development. Some of the authors declared receiving personal fees and/or grants from various sources including Amgen.

Source: Thierry AR et al. JAMA Netw Open. 2021 Sep 8. doi: 10.1001/jamanetworkopen.2021.24483.

Key clinical point: This large-scale prospective study found a positive linear association between fasting blood glucose (FBG), particularly FBG 126 mg/dL or more, and the risk for colorectal cancer (CRC) in patients without self-reported diabetes mellitus and colorectal polyps.

Major finding: FBG 126 mg/dL or more was associated with a 67% increased risk for CRC (adjusted hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.01-2.76) and a lower overall survival among long-term survivors (P < .05). When FBG was increasing per mmol/L, the HR for CRC risk at FBG 126 mg/dL or more was 1.27 (95% CI, 1.06-1.53).

Study details: The data come from a prospective study of 11,632 participants without a history of self-reported diabetes mellitus and colorectal polyps.

Disclosures: The authors did not disclose any specific source of funding. The authors declared no conflict of interests.

Source: Wu J et al. Medicine (Baltimore). 2021 Aug 27. doi: 10.1097/MD.0000000000026974.

Key clinical point: This large-scale prospective study found a positive linear association between fasting blood glucose (FBG), particularly FBG 126 mg/dL or more, and the risk for colorectal cancer (CRC) in patients without self-reported diabetes mellitus and colorectal polyps.

Major finding: FBG 126 mg/dL or more was associated with a 67% increased risk for CRC (adjusted hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.01-2.76) and a lower overall survival among long-term survivors (P < .05). When FBG was increasing per mmol/L, the HR for CRC risk at FBG 126 mg/dL or more was 1.27 (95% CI, 1.06-1.53).

Study details: The data come from a prospective study of 11,632 participants without a history of self-reported diabetes mellitus and colorectal polyps.

Disclosures: The authors did not disclose any specific source of funding. The authors declared no conflict of interests.

Source: Wu J et al. Medicine (Baltimore). 2021 Aug 27. doi: 10.1097/MD.0000000000026974.

Key clinical point: This large-scale prospective study found a positive linear association between fasting blood glucose (FBG), particularly FBG 126 mg/dL or more, and the risk for colorectal cancer (CRC) in patients without self-reported diabetes mellitus and colorectal polyps.

Major finding: FBG 126 mg/dL or more was associated with a 67% increased risk for CRC (adjusted hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.01-2.76) and a lower overall survival among long-term survivors (P < .05). When FBG was increasing per mmol/L, the HR for CRC risk at FBG 126 mg/dL or more was 1.27 (95% CI, 1.06-1.53).

Study details: The data come from a prospective study of 11,632 participants without a history of self-reported diabetes mellitus and colorectal polyps.

Disclosures: The authors did not disclose any specific source of funding. The authors declared no conflict of interests.

Source: Wu J et al. Medicine (Baltimore). 2021 Aug 27. doi: 10.1097/MD.0000000000026974.

Key clinical point: The proportion of patients at average risk who are up to date on colorectal cancer (CRC) screening has increased between 2011-2019, with multitarget stool DNA (mt-sDNA) assay being increasingly popular.

Major finding: More individuals aged 50-75 years considered at average risk for CRC were up to date on CRC screening in 2019 vs 2011 (69.7% vs 50.4%). The use of high-sensitivity fecal occult blood tests reduced between 2011 and 2019 (17.4% to 6.6%), whereas the use of mt-sDNA increased (1.9% in 2016-2017 vs 14.2% in 2018-2019).

Study details: This United States cohort study (n=97,776) examined the use of CRC screening before (August 1, 2011 to July 31, 2014) and after (August 1, 2016 to July 31, 2019) the mt-sDNA test became available.

Disclosures: This study was funded by Exact Sciences Corporation. Some of the authors including the lead author declared receiving personal fees, grants, consultancy, and/or serving on advisory board for various sources including Exact Sciences. Dr. Miller-Wilson reported being an employee of Exact Sciences. Ms. Princic and Ms. Wilson reported being employed by IBM Watson Health, which was paid by Exact Sciences to conduct this research.

Source: Fisher DA et al. JAMA Netw Open. 2021 Sep 2. doi: 10.1001/jamanetworkopen.2021.22269.

Key clinical point: The proportion of patients at average risk who are up to date on colorectal cancer (CRC) screening has increased between 2011-2019, with multitarget stool DNA (mt-sDNA) assay being increasingly popular.

Major finding: More individuals aged 50-75 years considered at average risk for CRC were up to date on CRC screening in 2019 vs 2011 (69.7% vs 50.4%). The use of high-sensitivity fecal occult blood tests reduced between 2011 and 2019 (17.4% to 6.6%), whereas the use of mt-sDNA increased (1.9% in 2016-2017 vs 14.2% in 2018-2019).

Study details: This United States cohort study (n=97,776) examined the use of CRC screening before (August 1, 2011 to July 31, 2014) and after (August 1, 2016 to July 31, 2019) the mt-sDNA test became available.

Disclosures: This study was funded by Exact Sciences Corporation. Some of the authors including the lead author declared receiving personal fees, grants, consultancy, and/or serving on advisory board for various sources including Exact Sciences. Dr. Miller-Wilson reported being an employee of Exact Sciences. Ms. Princic and Ms. Wilson reported being employed by IBM Watson Health, which was paid by Exact Sciences to conduct this research.

Source: Fisher DA et al. JAMA Netw Open. 2021 Sep 2. doi: 10.1001/jamanetworkopen.2021.22269.

Key clinical point: The proportion of patients at average risk who are up to date on colorectal cancer (CRC) screening has increased between 2011-2019, with multitarget stool DNA (mt-sDNA) assay being increasingly popular.

Major finding: More individuals aged 50-75 years considered at average risk for CRC were up to date on CRC screening in 2019 vs 2011 (69.7% vs 50.4%). The use of high-sensitivity fecal occult blood tests reduced between 2011 and 2019 (17.4% to 6.6%), whereas the use of mt-sDNA increased (1.9% in 2016-2017 vs 14.2% in 2018-2019).

Study details: This United States cohort study (n=97,776) examined the use of CRC screening before (August 1, 2011 to July 31, 2014) and after (August 1, 2016 to July 31, 2019) the mt-sDNA test became available.

Disclosures: This study was funded by Exact Sciences Corporation. Some of the authors including the lead author declared receiving personal fees, grants, consultancy, and/or serving on advisory board for various sources including Exact Sciences. Dr. Miller-Wilson reported being an employee of Exact Sciences. Ms. Princic and Ms. Wilson reported being employed by IBM Watson Health, which was paid by Exact Sciences to conduct this research.

Source: Fisher DA et al. JAMA Netw Open. 2021 Sep 2. doi: 10.1001/jamanetworkopen.2021.22269.